Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of AZD4573 in relapsed or refractory hematologic malignancies
NL-OMON50684Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of zemirciclib in hematopoietic malignancies, non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 6 more (2 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability, Biologically effective dose / maximum tolerated dose / recommended Phase II dose and 9 more. Started Oct 2017; status: completed.
02
Drugs
zemirciclib
03
Conditions
hematopoietic malignanciesnon-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)multiple myeloma (MM)Richter's syndrome (RS)
Beyond the preview
Go deeper on NL-OMON50684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50684.